The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologists

Gynecologic Oncology

Volumn 119, Issue 1, 2010, Pages 18-21

  Dewdney, Summer B ^a   Rimel, B J ^a   Reinhart, Andrew J ^a   Kizer, Nora T ^a   Brooks, Rebecca A ^a   Massad, L Stewart ^a   Zighelboim, Israel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neoadjuvant chemotherapy; Ovarian cancer; Society of Gynecologic Oncologists; Survey

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL HYSTERECTOMY; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CHI SQUARE TEST; COMPUTER PROGRAM; CYTOREDUCTIVE SURGERY; FEMALE; HEALTH CARE SURVEY; HUMAN; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; SALPINGOOOPHORECTOMY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; CLINICAL PRACTICE; GYNECOLOGY; ONCOLOGY; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES;

CHEMOTHERAPY, ADJUVANT; FEMALE; GYNECOLOGY; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 77956630573     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.06.021     Document Type: Article

References (16)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, and J. Xu Cancer statistics CA Cancer J Clin 58 2008 71 96
2. C.T. Griffiths Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl Cancer Inst Monogr 42 1975 101 104
3. R.E. Bristow, R.S. Tomacruz, and D.K. Armstrong Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
4. G.D. Aletti, S.C. Dowdy, and B.S. Gostout Aggressive surgical effort and improved survival in advanced-stage ovarian cancer Obstet Gynecol 107 2006 77 85
5. D.S. Chi, J.B. Liao, L.F. Leon, and E.S. Venkatraman Identification of prognostic factors in advanced ovarian epithelial carcinoma Gynecol Oncol 82 2001 532 537
6. P.E. Schwartz, T.J. Rutherford, and J.T. Chambers Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival Gynecol Oncol 72 1999 93 99
7. I. Vergote, I. DeWever, W. Tjalma, and M. VanGramberen Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of two hundred and eighty-five patients Gynecol Oncol 71 1998 431 436
8. P.E. Schwartz, J.T. Chambers, and R. Makuch Neoadjuvant chemotherapy for advanced ovarian cancer Gynecol Oncol 53 1994 33 37
9. T. Onda, H. Kobayashi, and Nakanishi Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206 Gynecol Oncol 113 2009 57 62
10. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol Oncol 103 2006 1070 1076
11. R.E. Bristow, E.L. Eisenhauer, A. Santillan, and D.S. Chi Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction Gynecol Oncol 104 2007 480 490
12. S. Tangjitgamol, S. Manusirivithaya, M. Laopaiboon, and P. Lumbiganon Interval debulking surgery for advanced epithelial ovarian cancer Cochrane Database Syst Rev 2 2009 10.1002/14651858.CD006014.pub4 Art. No.: CD006014
13. Vergote EORTC-GCG/NCIC-CTG Randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer Int Gynecol Cancer Soc 2008 Abstract 2008-1767
14. C.G. Gerestein, D.W. van der Spek, and M.J. Eijkemans Prediction of residual disease after primary cytoreductive surgey for advanced-stage ovarian cancer Int J Gynecol Cancer 19 2009 1511 1515
15. D.S. Chi, O. Zivanovic, and M.J. Palayekar A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal, and peritoneal carcinoma Gynecol Oncol 112 2009 6 10
16. S.C. Dowdy, S.A. Mullany, and K.R. Brandt The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma Cancer 101 2004 346 352